COPENHAGEN - Danish biotechnology firm Genmab A/S (NASDAQ:GMAB) has lost its appeal in the second arbitration with Janssen Biotech, Inc., concerning the cancer drug daratumumab, marketed as DARZALEX FASPRO® in the United States. The appeal arbitrator upheld the original decision to dismiss Genmab's claims for additional milestone payments and a new 13-year royalty term for the subcutaneous formulation of daratumumab.
Genmab had contended that the subcutaneous version constituted a new licensed product under their agreement, which would entitle them to further financial compensation. However, the tribunal dismissed Genmab's claims, deciding that they should have been brought in a prior arbitration between the two companies.
Despite this legal setback, Genmab has stated that the arbitration appeal's conclusion will not impact their financial guidance for the year 2024. The company remains focused on its mission to improve patients' lives through innovative antibody therapeutics. Over its more than two-decade history, Genmab has established over 20 strategic partnerships within the biotech and pharmaceutical industries to develop and deliver novel antibody therapies.
InvestingPro Insights
In light of Genmab's recent legal developments and their steadfast commitment to financial projections for 2024, it's worth noting some key financial metrics and insights that could be of interest to investors. Genmab holds a market capitalization of approximately $18.76 billion and a P/E ratio of 29.85, reflecting a high earnings multiple that signals investor confidence in their growth prospects, despite recent setbacks. This is further supported by a robust revenue growth of 42.01% over the last twelve months as of Q3 2023, showcasing the company's strong performance in revenue generation.
From an InvestingPro perspective, two notable tips stand out: Genmab is a prominent player in the Biotechnology industry, and analysts predict the company will be profitable this year, which aligns with their optimistic financial guidance. Additionally, Genmab's cash flows can sufficiently cover interest payments, and its liquid assets exceed short-term obligations, providing a degree of financial stability.
For those interested in a deeper analysis, InvestingPro offers a wealth of additional tips that can guide investment decisions. As a special New Year offer, a subscription to InvestingPro is now available at a discount of up to 50%. Use coupon code SFY24 to get an additional 10% off a 2-year InvestingPro+ subscription, or SFY241 to get an additional 10% off a 1-year InvestingPro+ subscription. With 9 more InvestingPro Tips available, investors can gain comprehensive insights into Genmab's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.